Literature DB >> 1414228

Intravenous gamma globulin in progressive MS.

S D Cook1, R Troiano, C Rohowsky-Kochan, A Jotkowitz, L Bielory, P D Mehta, J Oleske, S Bansil, P C Dowling.   

Abstract

In an attempt to prevent disease exacerbations, intravenous gamma globulin (500 mg to 2 g/kg) plus methylprednisolone was administered monthly to 14 patients with progressive multiple sclerosis, 11 of whom were steroid dependent. Seventeen exacerbations of disease activity were seen in 11 patients over a mean follow-up period of 7.8 months. Four exacerbations occurred in 3 patients within one month of receiving 1.6 to 2.0 g/kg of intravenous gamma globulin (IVGG). Most exacerbations occurred within 2 weeks of steroids being tapered; thus a steroid sparing effect of IVGG could not be demonstrated. We conclude that IVGG plus methylprednisolone can be given safely at monthly intervals for a prolonged period but in the dosage administered did not prevent exacerbations in 80% of patients with progressive multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1414228     DOI: 10.1111/j.1600-0404.1992.tb05061.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  5 in total

1.  Intravenous gammaglobulin treatment in chronic progressive multiple sclerosis.

Authors:  G Salemi; L Manfrè; S Monaco; T Angileri; P Aridon; S Pappalardo; P Ragonese; S Conte; G Savettieri
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 2.  Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis.

Authors:  Ales Dudesek; Uwe K Zettl
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

Review 3.  Multiple sclerosis: it epidemiological, genetic, and health care impact.

Authors:  R Williams; A S Rigby; M Airey; M Robinson; H Ford
Journal:  J Epidemiol Community Health       Date:  1995-12       Impact factor: 3.710

Review 4.  Promotion of remyelination by polyclonal immunoglobulin in Theiler's virus-induced demyelination and in multiple sclerosis.

Authors:  B G van Engelen; D J Miller; K D Pavelko; O R Hommes; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

Review 5.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.